A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults

MedImmune logo

MedImmune

Status and phase

Completed
Phase 2

Conditions

Asthma

Treatments

Biological: MEDI528 300 mg
Biological: MEDI528 30 mg
Other: Placebo
Biological: MEDI528 100 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT00968669
MI-CP198

Details and patient eligibility

About

To study the effectiveness and safety of multiple-doses of MEDI-528 on asthma control in adult participants with uncontrolled, moderate-to-severe, persistent asthma.

Full description

The primary objective of this study is to evaluate the effect of multiple-dose subcutaneous (SC) administration of MEDI-528 on asthma control in adults with uncontrolled, moderate-to-severe, persistent asthma.

Enrollment

329 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Subjects must meet all of the following criteria:

  • Male or female
  • Age 18 through 65 years at the time of screening
  • Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations

Female subjects of childbearing potential who are sexually active with non-sterilized male partner must use adequate contraception from screening through the end of the study. An acceptable method of contraception is defined as one that has no higher than a 1% failure rate. Sustained abstinence is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception

  • Non-sterilized males who are sexually active with a female of child-bearing potential must use adequate contraception from screening through the end of the study
  • Females or female partners not of childbearing potential must have been surgically sterilized (eg, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or postmenopausal (defined as at least 1 year since last regular menses)
  • Sterilized males must be at least 1-year post vasectomy and have obtained documentation of the absence of sperm in the ejaculate
  • Weight ≥ 45 kg but ≤ 120 kg and body mass index (BMI) between 18 and 35 kg/m2
  • Physician-diagnosed asthma by medical chart
  • Currently taking inhaled corticosteroids (ICS) or is a candidate to receive ICS per Expert Panel Report (EPR)-3
  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) value ≥ 40% at Day -28 and Day 1

A post-bronchodilator increase in FEV1 and/or FVC ≥ 12% and ≥ 200 mL at Day -28 OR meeting any one of the following criteria:

  • Proof of post-bronchodilator reversibility of airflow obstruction ≥ 12% documented within 36 months prior to randomization or proof of a positive response to a methacholine challenge documented within 36 months prior to randomization; OR
  • Proof of partial reversibility of ≥ 8% to < 12% improvement in post-bronchodilator FEV1 on Day -28 and achievement of ≥ 12% reversibility at a second time between Day -27 and Day -15; OR
  • If a) and b) are not met and all other inclusion/exclusion criteria are met, subjects with a FEV1 of ≥ 1.5 L and ≥ 60% on Day -14 will be eligible to undergo a methacholine challenge. If the subject achieves a positive response to this methacholine challenge, then this criterion is met

Uncontrolled asthma consistent with EPR-3. In the 28 days before screening, subjects should have a history of one or more of the following:

  • Daytime asthma symptoms ≥ 2 days/week
  • Nighttime awakening ≥ 1 night/week
  • Albuterol/salbutamol use ≥ 2 days/week
  • An Asthma Control Questionnaire (ACQ) score ≥ 1.5 at Day -28 and at Day 1.
  • At least one asthma exacerbation in the 12 months before screening that required intake of systemic corticosteroids after an unscheduled medical encounter or as agreed with a physician based on an asthma action plan that defines when oral steroids can be taken by the subject
  • Ability and willingness to complete the follow-up period through Day 323 as required by the protocol.

Exclusion Criteria

Any of the following would exclude the subject from participation in the study:

  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
  • Concurrent enrollment in another clinical study
  • Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals
  • Known history of allergy or reaction to any component of the investigational product formulation
  • History of anaphylaxis to other biologic therapy
  • Lung disease other than asthma (eg, chronic obstructive pulmonary disease [COPD], cystic fibrosis)
  • Severe depression as measured by a depression score > 15 on the Hospital Anxiety and Depression Scale (HADS) at either Day-28 or Day 1.
  • History of suicidal behavior in the previous 3 years as measured by the Columbia Suicide Severity Rating Scale (C-SSRS) at Day -28.
  • Acute illness other than asthma at the screening and randomization visits
  • History of an active infection within 28 days before and during the screening period, or evidence of clinically significant active infection, including ongoing chronic infection
  • History of ingestion of untreated water in a location known to be infected with parasites, resulting in acute or chronic diarrhea; history of recent travel to areas where parasite infestations are endemic within 6 months before screening; or a diagnosis of parasitic infection within 6 months before screening
  • Use of immunosuppressive medication (except oral prednisone up to a dose of 20 mg every other day or equivalent [eg, 10 mg a day or 5 mg twice a day] and inhaled and topical corticosteroids) within 28 days before randomization
  • Receipt of immunoglobulin or blood products within 28 days before randomization
  • Plans to donate blood during the entire study period
  • Donated blood or has had a blood transfusion within 28 days before screening
  • Receipt of any non-biological study drugs or interventional therapy (including surgical procedures) within 28 days of the first dose of investigational product in this study
  • Receipt of any biologicals including MEDI-528 within 5 half-lives before the first dose of investigational product in this study
  • History of any known immunodeficiency disorder
  • A positive hepatitis B surface antigen, or hepatitis C virus antibody, as determined by medical history and/or subject's verbal report
  • A positive human immunodeficiency virus test or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report
  • A live attenuated vaccination received within 28 days before screening
  • History of clinically significant abnormality on electrocardiogram (ECG) in the opinion of the investigator
  • Breastfeeding or lactating
  • History of treatment for alcohol or drug abuse within the past year
  • History suggestive of COPD or of tobacco smoking ≥ 10 pack-years
  • Evidence of any uncontrolled systemic disease upon physical examination
  • History of cancer, apart from basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 1 year before Day 1 or other malignancies treated with apparent success with curative therapy ≥ 5 years before screening
  • Any noninfectious disease involving multiple organs (eg, cystic fibrosis, systemic lupus erythematosus, hemophilia, multiple sclerosis, etc.) that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
  • Individuals who are legally institutionalized

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

329 participants in 4 patient groups

MEDI528 30 mg
Experimental group
Description:
MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
Treatment:
Biological: MEDI528 30 mg
MEDI528 100 mg
Experimental group
Description:
MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
Treatment:
Biological: MEDI528 100 mg
MEDI528 300 mg
Experimental group
Description:
MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
Treatment:
Biological: MEDI528 300 mg
Placebo
Experimental group
Description:
Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems